Blockade of Arf1-mediated lipid metabolism in cancers promotes tumor infiltration of cytotoxic T cells via the LPE-PPARγ-NF-κB-CCL5 pathway

  • Na Wang ,
  • Tiange Yao ,
  • Chenfei Luo ,
  • Ling Sun ,
  • Yuetong Wang ,
  • Steven X. Hou
Expand
  • Department of Cell and Developmental Biology at School of Life Sciences, State Key Laboratory of Genetic Engineering, Institute of Metabolism and Integrative Biology, Human Phenome Institute, Fudan University, Shanghai 200438, China
ytwang@fudan.edu.cn
stevenhou@fudan.edu.cn

Received date: 06 Jun 2023

Revised date: 30 Aug 2023

Accepted date: 04 Sep 2023

Copyright

2023 The Author(s) 2023. Published by Oxford University Press on behalf of Higher Education Press.

Abstract

Tumor immunotherapy has achieved breakthroughs in a variety of tumors. However, the systemic absence of T cells in tumors and immunosuppressive tumor microenvironment so far limits the efficacy of immunotherapy to a small population of patients. Therefore, novel agents to increase T-cell tumor infiltration are urgently needed in the clinic. We recently found that inhibition of the ADP-ribosylation factor 1 (Arf1)-mediated lipid metabolism not only kills cancer stem cells (CSCs) but also elicits an anti-tumor immune response. In this study, we revealed a mechanism that targeting Arf1 promotes the infiltration of cytotoxic T lymphocytes (CTLs) into tumors through the C-C chemokine ligand 5 (CCL5)-C-C chemokine receptor type 5 (CCR5) pathway. We found that blockage of Arf1 induces the production of the unsaturated fatty acid (PE 18:1) that binds and sequestrates peroxisome proliferator-activated receptor-γ (PPARγ) from the PPARγ-nuclear factor-κB (NF-κB) cytoplasmic complex. The released NF-κB was then phosphorylated and translocated into the nucleus to regulate the transcription of chemokine CCL5. CCL5 promoted infiltration of CTLs for tumor regression. Furthermore, the combination of the Arf1 inhibitor and programmed cell death protein 1 (PD-1) blockade induced an even stronger anti-tumor immunity. Therefore, targeting Arf1 represents a novel anti-tumor immune approach by provoking T-cell tumor infiltration and may provide a new strategy for tumor immunotherapy.

Cite this article

Na Wang , Tiange Yao , Chenfei Luo , Ling Sun , Yuetong Wang , Steven X. Hou . Blockade of Arf1-mediated lipid metabolism in cancers promotes tumor infiltration of cytotoxic T cells via the LPE-PPARγ-NF-κB-CCL5 pathway[J]. Life Metabolism, 2023 , 2(5) : 225 -237 . DOI: 10.1093/lifemeta/load036

1
Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823–33.

DOI

2
Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122–33.

DOI

3
Zaretsky JM, Garcia-Diaz A, Shin DS et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016;375:819–29.

DOI

4
Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer 2020;20:662–80.

DOI

5
Tumeh PC, Harview Christina L, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568–71.

DOI

6
Binnewies M, Roberts EW, Kersten K et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018;24:541–50.

DOI

7
Ganesh K, Massague J. TGF-β inhibition and immunotherapy: checkmate. Immunity 2018;48:626–8.

DOI

8
Wellenstein MD, de Visser KE. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity 2018;48:399–416.

DOI

9
Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol 2017;17:559–72.

DOI

10
Jain S, Annett SL, Morgan MP et al. The cancer stem cell niche in ovarian cancer and its impact on immune surveillance. Int J Mol Sci 2021;22:4091.

DOI

11
Baldominos P, Barbera-Mourelle A, Barreiro O et al. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell 2022;185:1694–708.e19.

DOI

12
Kaczmarek B, Verbavatz JM, Jackson CL. GBF1 and Arf1 function in vesicular trafficking, lipid homeostasis and organelle dynamics. Biol Cell 2017;109:391–9.

DOI

13
Donaldson JG, Jackson CL. ARF family G proteins and their regulators: roles in membrane transport, development and disease. Nat Rev Mol Cell Biol 2011;12:362–75.

DOI

14
D’Souza-Schorey C, Chavrier P. ARF proteins: roles in membrane traffic and beyond. Nat Rev Mol Cell Biol 2006;7:347–58.

DOI

15
Wang G, Xu J, Zhao J et al. Arf1-mediated lipid metabolism sustains cancer cells and its ablation induces anti-tumor immune responses in mice. Nat Commun 2020;11:220.

DOI

16
Casalou C, Faustino A, Barral DC. Arf proteins in cancer cell migration. Small GTPases 2016;7:270–82.

DOI

17
Lang L, Shay C, Zhao X et al. Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics. J Exp Clin Cancer Res 2017;36:112.

DOI

18
Lopez-Cotarelo P, Gomez-Moreira C, Criado-Garcia O et al. Beyond chemoattraction: multifunctionality of chemokine receptors in leukocytes. Trends Immunol 2017;38:927–41.

DOI

19
Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol 2001;2:102–7.

DOI

20
Blanpain C, Buser R, Power CA et al. A chimeric MIP 1aRANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors. J Leukoc Biol 2001;69:977–85.

DOI

21
Aldinucci D, Borghese C, Casagrande N. The CCL5/CCR5 axis in cancer progression. Cancers (Basel) 2020;12:1765.

DOI

22
Velasco-Velázquez M, Xolalpa W, Pestell RG et al. The potential to target CCL5/CCR5 in breast cancer. Expert Opin Ther Targets 2014;18:1265–75.

DOI

23
Monsalve FA, Pyarasani RD, Delgado-Lopez F et al. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm 2013;2013:549627.

DOI

24
Grygiel-Górniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications—a review. Nutr J 2014;13:17.

DOI

25
Christofides A, Konstantinidou E, Jani C et al. The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. Metabolism 2021;114:154338.

DOI

26
Marion-Letellier R, Savoye G, Ghosh S. Fatty acids, eicosanoids and PPAR gamma. Eur J Pharmacol 2016;785:44–9.

DOI

27
Singh SR, Zeng X, Zhao J et al. The lipolysis pathway sustains normal and transformed stem cells in adult Drosophila. Nature 2016;538:109–13.

DOI

28
Wang G, Yin W, Shin H et al. Neuronal accumulation of peroxidated lipids promotes demyelination and neurodegeneration through the activation of the microglial NLRP3 inflammasome. Nature Aging 2021;1:1024–37.

DOI

29
Hammond VJ, Morgan AH, Lauder S et al. Novel keto-phospholipids are generated by monocytes and macrophages, detected in cystic fibrosis, and activate peroxisome proliferator-activated receptor-γ. J Biol Chem 2012;287:41651–66.

DOI

30
Morgan AH, Dioszeghy V, Maskrey BH et al. Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease. J Biol Chem 2009;284:21185–91.

DOI

31
Werts C, le Bourhis L, Liu J et al. Nod1 and Nod2 induce CCL5/RANTES through the NF-κB pathway. Eur J Immunol 2007;37:2499–508.

DOI

32
Li J, Eu JQ, Kong Li R et al. Targeting metabolism in cancer cells and the tumour microenvironment for cancer therapy. Molecules 2020;25:4831.

DOI

33
Hirschhorn T, Stockwell BR. The development of the concept of ferroptosis. Free Radic Biol Med 2019;133:130–43.

DOI

34
Stockwell BR, Jiang X. A physiological function for ferroptosis in tumor suppression by the immune system. Cell Metab 2019;30:14–5.

DOI

35
Wang W, Green M, Choi JE et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 2019;569:270–4.

DOI

36
Liao P, Wang W, Wang W et al. CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell 2022;40:365–78.e6.

DOI

37
Garcia-Bates TM, Lehmann GM, Simpson-Haidaris PJ et al. Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies. PPAR Res 2008;2008:834612.

DOI

Outlines

/